|

RMC-5127 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Revolution Medicines, Inc.1

Indications

  • PDAC1
  • Lung Cancer (NSCLC)1
  • CRC1
  • Pancreatic Ductal Adenocarcinoma (PDAC)1
  • Non-small Cell Lung Cancer (NSCLC)1

Grand Rapids, Michigan1 trial

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

START Midwest

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.